Cargando…
Stem cell-based therapy for α(1)-antitrypsin deficiency
Human induced pluripotent stem cells offer the possibility of generating unlimited quantities of cells for autologous transplantation. By correcting the genetic defect underlying Z-allele α(1)-antitrypsin deficiency, we recently provided the first proof of principle for application of human induced...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340548/ https://www.ncbi.nlm.nih.gov/pubmed/22340671 http://dx.doi.org/10.1186/scrt95 |
| _version_ | 1782231471949348864 |
|---|---|
| author | Rashid, S Tamir Lomas, David A |
| author_facet | Rashid, S Tamir Lomas, David A |
| author_sort | Rashid, S Tamir |
| collection | PubMed |
| description | Human induced pluripotent stem cells offer the possibility of generating unlimited quantities of cells for autologous transplantation. By correcting the genetic defect underlying Z-allele α(1)-antitrypsin deficiency, we recently provided the first proof of principle for application of human induced pluripotent stem cells in the treatment of inherited genetic disorders. Several important safety concerns will need to be addressed before this can be translated into clinical practice. |
| format | Online Article Text |
| id | pubmed-3340548 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2012 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-33405482013-02-09 Stem cell-based therapy for α(1)-antitrypsin deficiency Rashid, S Tamir Lomas, David A Stem Cell Res Ther Commentary Human induced pluripotent stem cells offer the possibility of generating unlimited quantities of cells for autologous transplantation. By correcting the genetic defect underlying Z-allele α(1)-antitrypsin deficiency, we recently provided the first proof of principle for application of human induced pluripotent stem cells in the treatment of inherited genetic disorders. Several important safety concerns will need to be addressed before this can be translated into clinical practice. BioMed Central 2012-02-09 /pmc/articles/PMC3340548/ /pubmed/22340671 http://dx.doi.org/10.1186/scrt95 Text en Copyright ©2012 BioMed Central Ltd |
| spellingShingle | Commentary Rashid, S Tamir Lomas, David A Stem cell-based therapy for α(1)-antitrypsin deficiency |
| title | Stem cell-based therapy for α(1)-antitrypsin deficiency |
| title_full | Stem cell-based therapy for α(1)-antitrypsin deficiency |
| title_fullStr | Stem cell-based therapy for α(1)-antitrypsin deficiency |
| title_full_unstemmed | Stem cell-based therapy for α(1)-antitrypsin deficiency |
| title_short | Stem cell-based therapy for α(1)-antitrypsin deficiency |
| title_sort | stem cell-based therapy for α(1)-antitrypsin deficiency |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340548/ https://www.ncbi.nlm.nih.gov/pubmed/22340671 http://dx.doi.org/10.1186/scrt95 |
| work_keys_str_mv | AT rashidstamir stemcellbasedtherapyfora1antitrypsindeficiency AT lomasdavida stemcellbasedtherapyfora1antitrypsindeficiency |